Genetic Diseases Malaria
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: i. Participant of RTS,S/AS01E -SMC trial (initial and extension components). ii. Provision of informed consent by a parent or legally recognized guardian for the child. iii. Received all the RTS,S/AS01E or control vaccines as defined in the trial protocols (primary series in April, May, and June 2017, plus booster or control vaccine each year until the child reached 5 years of age).
Exclusion criteria
Exclusion criteria: i. Did not receive the study vaccines as defined in the trial protocols. ii. Dry blood spots not collected during the cross-sectional surveys or missing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Natural log mean fluorescent intensity (MFI) of antibody responses to 15 antigenic markers | — |
Secondary
| Measure | Time frame |
|---|---|
| Mean percentage change in avidity of antibody responses to 15 antigenic markers | — |
Countries
Mali
Contacts
Dean of the Faculty of Pharmacy Universite des Sciences des Techniques et des Technologies de Bamako